# Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

> **NCT02509507** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 127 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Metastases
- Cutaneous or Subcutaneous Lymph Node
- Liver Tumors

## Interventions

- **DRUG:** Talimogene Laherparepvec
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02509507
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-05
- **Primary completion:** 2022-02-14
- **Final completion:** 2023-07-11
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509507, "Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02509507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*